Interestingly, Alpelisib (BYL719), a specific PIK3CA inhibitor, has shown a higher efficacy than Rapamycin in the treatment of PIK3CA-related overgrowth syndromes (PROS) in mice and humans56. The gene discussed is PIK3CA; the disease is overgrowth syndrome.